Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends marketing authorization for HRA's emergency contraceptive ellaOne

March 24, 2009

Bristol-Myers Squibb withdraws marketing authorization application for Ixempra

March 23, 2009

EMEA recommends continued vaccination with Gardasil

Feb. 23, 2009

FDA issues public health advisory for Raptiva, EMEA recommends suspension

Feb. 23, 2009

CHMP recommends granting marketing authorization to Nycomed's Pantozol Control

Feb. 20, 2009

Merck Sharp & Dohme withdraws MAA to EMEA for vorinostat MSD in CTCL

Feb. 19, 2009

CHMP recommends new indication for Nycomed's TachoSil

Dec. 29, 2008

CHMP recommends marketing authorization for Pfizer's Fablyn in osteoporosis

Dec. 29, 2008

Oncoscience withdraws Theraloc (nimotuzumab) marketing authorization application

Dec. 5, 2008

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

Nov. 25, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Science
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Asia
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...